Chemo-free triplet produces ‘favorable’ results in advanced disease

Mantle cell lymphoma
A chemotherapy-free combination regimen has demonstrated “favorable” safety and efficacy in patients with advanced chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), according to researchers. They found that treatment with ublituximab, umbralisib, and ibrutinib produced responses in patients with CLL/SLL, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL). [Read Article]

Inhibitor elicits responses in heavily pretreated FL, DLBCL

14th International Conference
 on Malignant Lymphoma (ICML)
Interim results of a phase 2 trial suggest tazemetostat can be effective in patients with heavily pretreated, relapsed or refractory non-Hodgkin lymphoma. The EZH2 inhibitor produced the highest overall response rate in patients with EZH2-mutated follicular lymphoma (FL), followed by EZH2-mutated diffuse large B-cell lymphoma (DLBCL). However, the drug also produced complete responses in FL and DLBCL patients with wild-type EZH2. “If we had focused [only] on patients with EZH2 mutations, we would have missed those other complete responders in the wild-type setting,” said study investigator Franck Morschhauser, MD, PhD, of Centre Hospitalier . . . [Read Article]

New frontline treatments needed for Hodgkin lymphoma

Anna Sureda, MD, PhD
In this editorial, Anna Sureda, MD, PhD, of the Institut Català d'Oncologia, Hospital Duran i Reynals, in Barcelona, Spain, details the need for new frontline treatments for patients with Hodgkin lymphoma, including those with advanced stage disease. She describes the gap in outcomes with current treatment regimens between patients with early- and late-stage disease, and emphasizes the need to balance efficacy and safety when developing new treatments. [Read Article]